Overcoming neoantigen insufficiency in melanoma immunotherapy
15 March 2017 12:00 to 13:00 EDT
220 Mass. Avenue, Cambridge MA - USA
Speaker: David E. Fisher MD, PhD Director, Melanoma Program MGH Cancer Center Chief, Dept of Dermatology, MGH
Seminar Abstract: Pathways of oncogenic transformation in melanocytes will be discussed, as well as the presentation of model systems that test the roles of UV-induced neo-antigens in immune checkpoint inhibitor therapies. Several strategies designed to overcome neoantigen insufficiency will be presented. These will aim to provide mechanistic insights to tumor immune recognition as well as clinically tractable strategies for human therapeutic applications.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Speaker | David E. Fisher MD, PhD
Dr. Fisher holds a PhD in Immunology from Rockefeller University, MD from Cornell Medical College, Postdoc with Phillip Sharp, and trained clinically at Mass General Hospital, Dana-Farber Cancer Institute, and Boston Children’s Hospital. His laboratory has discovered fundamental pathways involved in skin pigmentation, its regulation by the environment, formation of melanoma, and treatment strategies for melanoma. He directs the Melanoma Program at MGH, and co-directs it across Harvard Medical School.